INVESTOR RELATIONS

ETAO International is committed to creating long-term value for investors through strategic global expansion, advanced technological integration, and responsible corporate governance. We provide transparent financial information and clear strategic insights, supporting informed investment decisions and robust stakeholder relationships.

Start Now

Financial Highlights

Consolidated Revenue (Unaudited, 2024)

>$150 Million USD

Pro Forma Revenue Projection (2025, with Strategic Acquisitions)

>$660 Million USD

Strategic Acquisitions (Completed)

HiPatho: Digital pathology
DiaCarta: Precision diagnostics
6D Dental: AI dental imaging

IPO & Nasdaq Relisting Timeline

ETAO International is strategically positioned for a strong return to Nasdaq, providing significant valuation and liquidity benefits to our stakeholders.

Key Milestones

Timeframe	Progress
Q1 2025	Legal and strategic planning completed
Q2 2025	Finalize formal acquisition agreements; regulatory approvals and integration planning
Q3 2025	Complete operational integration
Q4 2025	Full operational consolidation; Nasdaq relisting completed

Capital and Investment Strategy

Funding Sources

Internal cash reserves, PIPE funding, and strategic equity partners.
Supported by international investors, private equity firms, and experienced investment banking syndicates.

Strategic Investment Objectives

Acquire profitable or near-profitable healthcare businesses, especially within the dental, AI-driven medical technology, and precision diagnostics sectors.
Co-invest in U.S.-based healthcare assets demonstrating clear operational scalability, strong market potential, and integration synergy with ETAO’s digital ecosystem.

Target Deal Size

China: $100 Million and above per deal.
U.S.: Flexible, tailored to synergy potential and operational scalability.

Governance
& Compliance

ETAO operates under a robust governance framework designed to ensure compliance, transparency, and strong stakeholder confidence.

Corporate Governance

Cayman Islands-registered entity with U.S.-incorporated operations, fully compliant with SEC and Nasdaq regulatory standards.
Experienced leadership team and board with deep expertise in healthcare, finance, AI technology, and public market operations.

Board of Directors & Leadership
Wilson Liu: Chairman & CEO; extensive Wall Street and cross-border M&A experience.
Jason Chang: COO; healthcare IT and AI integration specialist, former executive at Siemens Healthcare and Microsoft.
Tong Zang: CIO; neuroscientist and healthcare investment professional, former Alibaba-affiliated fund director.